|
시장보고서
상품코드
2076261
단클론항체 치료제 시장 : 원료별, 용도별, 유통 채널별, 지역별Monoclonal Antibody Therapeutics Market, By Source, By Application, By Distribution Channel, And by Region |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
단클론항체 치료제 시장은 2026년에 3,096억 5,780만 달러 규모에 달할 것으로 추정되며, 2033년에 8,137억 2,060만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 14.8%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 3,096억 5,780만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026-2033년까지 예측 기간의 CAGR: | 14.80% | 2033년 시장 규모 예측: | 8,137억 2,060만 달러 |
면역계는 세균이나 바이러스 등의 병원체를 감지하고 파괴하는 복잡한 메커니즘으로 구성되어 있습니다. 마찬가지로, 이 시스템은 암세포 등 손상된 세포를 제거하기도 합니다. 면역 체계가 침입자를 발견하고 파괴하는 방법 중 하나는 항체의 작용입니다. 단클론항체 요법은 특정 세포나 단백질에 특이적으로 결합하는 단클론항체(mAbs)를 사용하는 면역요법의 일종입니다. 이 치료의 목적은 환자의 면역계를 자극하여 해당 세포를 공격하게 하는 데 있습니다. 지난 몇 년 동안 CTLA-4, PD-1, PD-L1 등의 면역 체크포인트에 작용하며 독자적인 작용 기전을 가진 다양한 단클론항체들이 승인되어 왔습니다. 각 제약사는 암에서 희귀질환에 이르기까지 다양한 질환을 치료하기 위해 여러 분류에 속하는 의약품 개발에 주력하고 있습니다. 항암제와 병용되는 단클론항체는 다양한 암을 치료하기 위한 효과적인 선택지로 자리 잡고 있습니다. 또한 2020년에는 COVID-19 치료를 목적으로 한 단클론항체 치료제 개발이 가속화되었습니다.
시장 역학
주요 규제 당국의 승인 획득 등 제품 포트폴리오 확대를 위한 성장 전략의 도입이 확대되고 있는 점이 예측 기간 동안의 시장 성장을 견인할 것으로 전망됩니다. 예를 들어, 2022년 2월, 미국 식품의약국(FDA)은 제약사 릴리가 제조하는 새로운 단클론항체 '베브테로비맙'에 대해 오마이크론 변이주에도 효과를 유지하는 COVID-19 치료제로서 긴급사용승인(EUA)을 발급했습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 단클론항체 치료제 시장의 주요 기업 개요을 발표하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 단클론항체 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 단클론항체 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활하게 의사결정을 내릴 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 단클론항체 치료제 시장 : 원료별
제5장 세계의 단클론항체 치료제 시장 : 용도별, 2021-2033년
제6장 세계의 단클론항체 치료제 시장 : 유통 채널별, 2021-2033년
제7장 세계의 단클론항체 치료제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSM 26.07.07Monoclonal Antibody Therapeutics Market is estimated to be valued at USD 3,09,657.8 Mn in 2026 and is expected to reach USD 8,13,720.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 14.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,09,657.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 14.80% | 2033 Value Projection: | USD 8,13,720.6 Mn |
The immune system is made up of a complex team of players that detect and destroy disease-causing agents, such as bacteria and viruses. Similarly, this system may eliminate damaged cells, such as cancer cells. One way the immune system finds and destroys invaders is with antibodies. Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAbs) to bind monospecifically to certain cells or proteins. The objective is that this treatment will stimulate the patient's immune system to attack those cells. Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. Also, there was a boost in the development of monoclonal antibody therapeutics for the treatment of COVID-19 in the year 2020
Market Dynamics
Increasing adoption of growth strategies, such as authorization by key regulatory authorities in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in February 2022, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for a new monoclonal antibody, bebtelovimab manufactured by Lilly, a pharmaceutical company for the treatment of COVID-19 that retains activity against the omicron variant.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global monoclonal antibody therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Pfizer Inc., Novartis AG, Bayer AG, Sanofi, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Merck KGaA, GSK plc., AbbVie Inc., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., AstraZeneca, AbCellera Biologics Inc., Molecular Depot LLC, DAIICHI SANKYO COMPANY, LIMITED., Abbott, Biogen, Thermo Fisher Scientific, Inc., Cell Signaling Technology, Inc, Intas Pharmaceuticals Ltd., Avantor Inc., UCB S.A., Merus N.V., GENEXTGENOMICS.COM, Biogenuix
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global monoclonal antibody therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global monoclonal antibody therapeutics market
Detailed Segmentation:
- Global Monoclonal Antibody Therapeutics Market, By Source (Revenue, USD Mn, 2021 - 2033)
- Human
- Chimeric
- Murine
- Humanized
- Global Monoclonal Antibody Therapeutics Market, By Application (Revenue, USD Mn, 2021 - 2033)
- Cancer
- Autoimmune Disease
- Hematological Disease
- Infectious Disease
- Others
- Global Monoclonal Antibody Therapeutics Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Monoclonal Antibody Therapeutics Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Country/Region
- Company Profiles
- Pfizer Inc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Bayer AG
- Sanofi
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Merck KGaA
- GSK plc.
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- AstraZeneca
- AbCellera Biologics Inc.
- Molecular Depot LLC
- DAIICHI SANKYO COMPANY, LIMITED.
- Abbott
- Biogen
- Thermo Fisher Scientific, Inc.
- Cell Signaling Technology, Inc
- Intas Pharmaceuticals Ltd.
- Avantor Inc.
- UCB S.A.
- Merus N.V.
- GENEXTGENOMICS.COM
- Biogenuix
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Source
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- Product Launch
- Technological Advancements
- PEST Analysis
- Regulatory Scenario
- Mergers and Acquisitions
4. Global Monoclonal Antibody Therapeutics Market, By Source, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Human
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Chimeric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Murine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Humanized
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Monoclonal Antibody Therapeutics Market, By Application, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Autoimmune Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Hematological Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Infectious Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Monoclonal Antibody Therapeutics Market, By Distribution Channel, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segments Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
7. Global Monoclonal Antibody Therapeutics Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Pfizer Inc.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Regeneron Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbCellera Biologics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Molecular Depot LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- DAIICHI SANKYO COMPANY, LIMITED.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Thermo Fisher Scientific, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cell Signaling Technology, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Intas Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Avantor, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- UCB S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merus N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GENEXTGENOMICS.COM
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biogenuix
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
